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Background: The histone demethylase GASC1 (JMJD2C) is an epigenetic factor suspected of involvement in
development of different cancers, including breast cancer. It is thought to be overexpressed in the more aggressive
breast cancer types based on mRNA expression studies on cell lines and meta analysis of human breast cancer sets.
This study aimed to evaluate the prognostic and predictive value of GASC1 for women with invasive breast cancer.
Methods: All the 355 cases were selected from a cohort enrolled in the Kuopio Breast Cancer Project between
April 1990 and December 1995. The expression of GASC1 was studied by immunohistochemistry (IHC) on tissue
microarrays. Additionally relative GASC1 mRNA expression was measured from available 57 cases.
Results: In our material, 56% of the cases were GASC1 negative and 44% positive in IHC staining. Women with
GASC1 negative tumors had two years shorter breast cancer specific survival and time to relapse than the women
with GASC1 positive tumors (p=0.017 and p=0.034 respectively). The majority of GASC1 negative tumors were
ductal cases (72%) of higher histological grade (84% of grade II and III altogether). When we evaluated estrogen
receptor negative and progesterone receptor negative cases separately, there was 2 times more GASC1 negative
than GASC1 positive tumors in each group (chi2, p= 0.033 and 0.001 respectively). In the HER2 positive cases, there
was 3 times more GASC1 negative cases than GASC1 positives (chi2, p= 0.029). Patients treated with radiotherapy
(n=206) and hormonal treatment (n=62) had better breast cancer specific survival, when they were GASC1 positive
(Cox regression: HR=0.49, p=0.007 and HR=0.33, p=0.015, respectively). The expression of GASC1 mRNA was in
agreement with the protein analysis.
Conclusions: This study indicates that the GASC1 is both a prognostic and a predictive factor for women with
invasive breast cancer. GASC1 negativity is associated with tumors of more aggressive histopathological types
(ductal type, grade II and III, ER negative, PR negative). Patients with GASC1 positive tumors have better breast
cancer specific survival and respond better to radiotherapy and hormonal treatment.
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Breast cancer is a heterogeneous disease with different
histopathological, molecular and clinical characteristics.
Moreover, there is a wide variation in the progress of
breast cancer in patients of the same age and with
tumors of comparable clinical extent. The discovery of
molecular markers, such as estrogen, progesterone and
HER2 receptors has facilitated the classification of
tumors and led to discovery of new cancer therapies.
However, the selection of patients for appropriate adju-
vant therapies still encounters difficulties [1]. Therefore
there is an urgent need for novel diagnostic, prognostic
and predictive markers which would make easier selection
of patients for adjuvant therapies and possibly open novel
perspectives for more efficient therapeutic strategies.
Nowadays epigenetics is making an increasingly
important impact in cancer research [2-4]. Epigenetic
research has not only provided novel insights into the
molecular mechanisms of cancer, but it has also revealed
useful diagnostic, prognostic and predictive biomarkers
[5-7]. In addition to epigenetic modifications like DNA
methylation and nucleosome positioning, histone modi-
fication patterns are altered in human tumors. However,
methodological difficulties prevent use of altered histone
modification profiles found in cancer as biomarkers [8].
Therefore, there is a considerable interest in understand-
ing histone modifier genes and their products. One
of these genes is GASC1 (gene amplified in squamous
cell carcinoma 1; aliases: JMJD2C, JHDM3C, KDM4C)
which codes a histone demethylase for di- and trimethy-
lated lysine 9 and 36 on histone H3 (H3K9me3/2 and
H3K36me3/2) [9,10]. H3K9me3/2 mark is generally
associated with transcriptional repression and the forma-
tion of heterochromatin, while H3K36me3/2 is asso-
ciated with transcriptionaly active genes and it is
believed to play an important role in the suppression of
incorrect transcription [10,11]. Because of its dual role
in modifying H3 either by removing the repressive
H3K9me3/2 or the active H3K36me3/2 factor, GASC1
has been considered to be a fine-tuning regulator of
gene expression in normal development and differenti-
ation as well as in cancer development and progression
[12-14]. The involvement of GASC1 in development
of breast cancer has been well documented in cell
lines by Liu et al. [13] and Wu at al. [15]. They demon-
strated that GASC1 is amplified and overexpressed in
multiple breast cancer cell lines, it causes transformation
of immortalized, non-transformed mammary epithelial
cells, regulates expression of genes responsible for
stem cells self-renewal and may be linked to the stem
cell phenotypes in breast cancer. Additionally, they
have found that the GASC1 is overexpressed in aggres-
sive, basal-like breast cancers compared with non basal-
like breast cancers.Moreover, an oncogenic role of GASC1 has been
documented in prostate cancer where it enhances the
transcription of androgen receptor-dependent genes and
cell proliferation by interaction with ligand-bound an-
drogen receptor [16]. GASC1 also plays an important
role in normal development and differentiation by regu-
lating expression of pluripotency genes, including
NOTCH1, NANOG, Sox2 and Pou5 [17,18].
As far as we are aware, this marker has not been eval-
uated by immunohistochemistry in human breast
tumors. Consequently, this study aimed at determining
the relevance of GASC1 demethylase in the prognosis of
invasive breast cancer progression and in the prediction
of responses to particular adjuvant treatments in mater-
ial from a large cohort of patients with a detailed clinical
and histopathological classification of tumors and up to
20 years of follow-up [19]. Additionally, we investigated
whether this marker could be utilized for more detailed
classification of invasive breast cancer.
Methods
Our initial material consisted of 392 breast cancer cases
selected from a cohort enrolled into the Kuopio Breast
Cancer Project in the Kuopio University Hospital, Kuopio,
Finland between April 1990 and December 1995 [20,21].
The tumor samples from these patients were fixed in
10% buffered formalin and embedded in paraffin. The
histological diagnosis was confirmed by reviewing one to
four original sections of the primary tumor. From the
total material (392 tumors), we excluded 37 benign and in
situ cases. In the remaining 355 cases of invasive breast
tumors without distant metastases, we evaluated GASC1
expression by immunohistochemical (IHC) staining in the
nuclei of the tumor epithelial cells (Figure 1). Further we
analyzed how the GASC1 status would influence the
breast cancer specific survival and the time to relapse.
In the analyzed by IHC material, 198 (55.8%) cases
were GASC1 negative and 157 (44.2%) GASC1 positive.
In this cohort, 105 patients had died of breast cancer,
106 patients had died from other causes than breast
cancer and 144 patients were still alive at the time of
analysis. The mean follow up time at the cut-off point
in February 2011 was 10.6 years, ranging from 0.1 to
20.4 years. Sixty eight patients had undergone resection,
285 were treated with mastectomy, and two patients
did not undergo surgery. Postoperative radiotherapy
was given to 206 patients. Altogether 62 patients
had received adjuvant tamoxifen, and 69 patients
were treated with adjuvant chemotherapy, mainly the
intravenous CMF regimen (500 mg/m2, methotrexate
40 mg/m2, 5-fluorouracil 500 mg/m).
The tissue microarray (TMA) was constructed as
described previously [22]. The diagnosis of the cases
was based on the World Health Organization (WHO),
Figure 1 Expression of GASC1 in invasive breast carcinoma of ductal type. (A) Positive immunostaining in nuclei of epithelial cells (arrows;
immunoscores: 3 for the nuclear number and 3 for intensity of nuclear staining), positive staining visible in cytoplasm was not taken into account.
Original magnification of x200. (B) Negative GASC1 immunostaining in nuclei of epithelial carcinoma cells. Original magnification of x200.
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The presence of metastases was determined at the time
of the operation. The collection of the material and the
clinical features of the patients have been described in a
previous study [21]. The research was approved by the
ethical committee of University of Kuopio/University of
Eastern Finland and Kuopio University Hospital.Immunohistochemistry for GASC1
Immunohistochemical staining was performed on 4 μm-
thick sections cut, from TMA block. After deparaffiniza-
tion and rehydration, the sections were heated in a
microwave oven for 3 × 5 min in citrate buffer (pH 6.0).
Then they were treated for 5 min with 5% hydrogen
peroxide to block endogenous peroxidase. Next, the sec-
tions were incubated for 35 min at room temperature in
1.5% normal serum diluted in PBS to block non-specific
binding. After that, the sections were incubated over-
night at 4°C with the mouse monoclonal anti – GASC1
antibody (Origene, TA 500587) at dilution 1:100. The
slides were then incubated with a biotinylated secondary
antibody (35 min) and avidin-biotin-peroxidase complex
(45 min) (ABC Vectastain Mouse Elite Kit, Vector La-
boratories, Burlingame, CA, USA). After each step of the
immunostaining procedure the slides were rinsed with
PBS. The color was developed with diaminobenzidine
tetrahydrochloride (DAB) (Sigma, St. Louis, MO, USA).
The slides were counterstained with Mayer’s haematoxy-
lin, washed, dehydrated, cleared and mounted with
Depex (BDH, Poole, UK). In the negative controls, the
primary antibody was omitted.
The immunoreactivity for GASC1 was analyzed in the
nuclei of epithelial tumor cells taking into account the
number of positively stained nuclei and intensity of
staining. The number of positively stained nuclei was
semiquantified as follows:
0-5% of nuclei stained = (0)
5-25% of nuclei stained = (1)25-75% of nuclei stained = (2)
75-100% of nuclei stained = (3)






The evaluation was performed on two separate array
cores (A and B) by two pathologists (YS, BB) blinded to
outcome (Figure 1). The results in series A and B were
similar (substantial inter-series agreement was achieved;
kappa for both nuclear number and intensity was 0.7;
p=0.000). The final score was obtained by combining
these results into four groups. Tumors were designated
as negative if their scores from both series A and B were
0. Tumors were designated as positive if their score from
at least one series was positive.mRNA expression analysis
For this study from this cohort there were 57 samples
available with invasive breast tumors. RNA was isolated
from fresh frozen tissue stored at −70°C using Protein
and RNA Isolation System for Small RNAs (mirVanaTM
ParisTM). We used High Capacity cDNA Reverse Tran-
scription Kit to synthesize cDNA (Applied Biosystems,
Foster City, USA) following the manufacturer’s instruc-
tions. The endogenous control gene was chosen by the
investigation conducted by McNeill et al. [24] where
they determined PPIA to be the best choice for breast
cancer mRNA analysis. Next we performed quantitative
real-time RT-PCR using gene specific TaqManW Gene
Expression Assays (Applied Biosystems). Relative gene
expression values were calculated as the ratio between
the target gene and the endogenous control PPIA,
obtained for each sample from the standard curves.
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nated as positives and lower than the mean as negatives.Statistical analysis
The expression of GASC1 in different groups was com-
pared using chi-squared test. In breast cancer specific
survival analysis, the end point was death from breast
cancer with deaths from other causes being censored,
whereas in time to relapse analysis, the end point was
breast cancer recurrence, either local or distant. Overall
survival was calculated from the date of diagnosis to the
date of death or the last follow-up date. Kaplan-Meier
analysis was applied to estimate breast cancer specific
survival and overall survival according to the adjuvant
treatment; different groups were compared with the log-
rank test. Multivariate analyses were conducted with the
Cox regression model. The statistical analyses were per-
formed using SPSS version 17.0 (SPSS Inc., Chicago, IL,
USA). p < 0.05 was considered statistically significant.
Results
GASC1 IHC negativity is an independent prognostic factor
of poorer breast cancer specific survival
Overall, women with GASC1 negative tumors (n=198)
had two years shorter breast cancer specific survival
than the women with GASC1 positive tumors (n=157;
Table 1, Figure 2). Stratification according to clinicalTable 1 Breast cancer specific survival by Kaplan-Meier
analysis according to clinical parameters





Overall 355 14.6 [198] 16.6 [157] 0.017
Age
<=55 172 15.0 [107] 16.3 [65] 0.292
>55 183 14.0 [91] 16.4 [92] 0.017 [0.019]
Tumor size
T1 168 16.6 [92] 17.0 [76] 0.376
T2+T3+T4 187 12.7 [106] 15.8 [81] 0.010 [0.749]
Nodal status
negative 193 17.1 [111] 18.0 [82] 0.109
positive 162 11.4 [87] 14.8 [75] 0.012 [0.520]
Clinical stage
I 120 17.8 [66] 17.8 [54] 0.579
II+III+IV 230 12.8 [130] 15.9 [100] 0.005 [0.820]
The p-values in the first column are calculated using Log Rank (Mantel-Cox)
test for equality of survival distributions for the different levels of GASC1
(significant p-values in bold). The p-values in the second column in the
squared brackets are calculated using Fisher’s exact test to examine if there is
a difference in proportion of GASC1 negative and positive cases in groups of
different clinical parameters. n – number of cases.parameters revealed that the GASC1 negative women,
over 55 years of age, with tumor size T2, T3 or T4, with
positive nodal status and with clinical stage II, III or IV
had a significantly poorer survival than the GASC1 posi-
tive ones. In patients aged 55 years or younger and
patients with clinical stage I, the GASC1 status did not
influence the survival time (Table 1).
After including the above clinical parameters as cov-
ariates in the Cox regression analysis, we confirmed that
GASC1 negativity was an independent factor predicting
poorer breast cancer specific survival, equal to the posi-
tive nodal status (p=0.001, Table 2, Figure 3). In this ana-
lysis tumor size (T2, T3 and T4) and clinical stage (II, III
and IV) had no effect on breast cancer specific survival
and time to relapse possibly, because there were only
34 patients (9.6%) with T3 and T4 tumors and 42
patients (12%) at Stage III and Stage IV in our material.
Probably, this number of cases was not sufficient to
show a significant influence on survival in multivariate
analysis. However, in univariate analysis the patients
with T1 and at Stage I survived significantly better and
had significantly longer time to relapse than the patients
with more advanced disease. Similarly, in bivariate ana-
lysis, where as the second variable in addition to tumor
size or Stage was entered GASC1 status, tumor size or
stage and GASC1 status had a significant effect on the
breast cancer specific survival and time to relapse.
GASC1 IHC negative cases have a shorter time to relapse
than the GASC1 positive cases
Overall, there were 132 cases with relapse and breast
cancer was the cause of death of 105 women. Eleven
women with a relapse died from other causes and 16
were still alive at the time of analysis. Women with
GASC1 negative tumors had a shorter time to relapse
than the women with GASC1 positive tumors (Table 3,
Figure 4). After stratification according to the clinical
parameters, the results were similar to those obtained in
breast cancer specific survival analysis, which suggests
that among subjects with more advanced stages of the
disease, GASC1 negative cases had poorer prognosis
(Table 3). Cox regression analysis verified that the
GASC1 negativity is an independent factor predicting a
shorter time to relapse in women with invasive breast
cancer (p=0.002, Table 2, Figure 5).
GASC1 IHC negative cases are more likely to have a
relapse of breast cancer and to suffer from more
aggressive tumors than the GASC1 positive cases
Among patients with a relapse (n=132) there were 26%
more GASC1 negative cases (n=83) than GASC1 posi-
tive (n=49), while among patients without relapse
(n=223) the difference between GASC1 negative (n=115)




















Figure 2 Breast cancer specific survival by Kaplan-Meier analysis. Overall, the patients with GASC1 immunopositive tumors have better
survival than the patients with GASC1 negative tumors (p=0.017 Log Rank; p=0.012, Breslow; p=0.013, Tarone-Ware).
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(72 %) of higher histological grade (84% of grade II and
III altogether). The GASC1 negative tumors significantly
differ in terms of histological type and grade, estrogen
receptor (ER), progesterone receptor (PR) and HER2
status from GASC1 positive tumors (p=0.005, p=0.000,Table 2 Analysis of breast cancer specific survival and time to
regression




>55 183 0.948 (0.638-1.408)
GASC1 status
positive 157
negative 198 2.040 (1.345-3.092)
Nodal status
negative 193
positive 162 3.177 (1.768-5.710)
Tumor size
T1 168
T2+T3+T4 187 0.621 (0.356-1.080)
Clinical stage
I 120
II+III+IV 230 1.107 (0.456-2.687)
unknown 5
n – number of cases, HR – hazard ratio.p=0.033, p=0.001 and p=0.029 respectively; Table 4).
The aforementioned results pointed to the possibility
that GASC1 negativity might only be a marker for
aggressive tumor subtype but not an independent
marker of breast cancer specific survival. To check this
possibility, we performed the Kaplan-Meier survivalrelapse in the whole group of patients by Cox
survival Time to relapse
p-value HR (95%CI) p-value
0.791 0.993 (0.698-1.413) 0.969
0.001 1.766 (1.230-2.535) 0.002
0.000 2.835 (1.702-4.723) 0.000
0.092 0.707 (0.431-1.161) 0.171




















Figure 3 Breast cancer specific survival analysis by Cox regression. After adjusting the model to confound for the age at diagnosis, nodal
status, size of tumor, and clinical stage, GASC1 positive patients have better survival than GASC1 negative. The p-value for the model is 0.000 and
for the GASC1 status 0.001.
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that the GASC1 negativity significantly worsened the sur-
vival in ductal cases (Log Rank p=0.006), ER positive
cases (Log Rank p=0.043) and HER2 negative cases (Log
Rank p=0.018; Table 5). Even after adjusting for histo-
logical type, histological grade, ER, PR, HER2 and nodal
status, GASC1 negativity was significantly associated with
poorer breast cancer specific survival (HR=2.0, p=0.004).Table 3 Time to relapse by Kaplan-Meier analysis





>55 183 12.9/ 91
Tumor size




positive 162 9.1/ 87
Clinical stage
I 120 16.2/ 66
II+III+IV 230 11.1/130
p-value for test of equality of survival distributions for the different levels of GASC1GASC1 IHC positivity is an independent marker for
better prognosis in patients treated with radiotherapy
or tamoxifen
We also analyzed the predictive value of GASC1 staining
according to the adjuvant treatments that the patients
were given. There were 206 patients who were treated with
adjuvant radiotherapy. Kaplan-Meier analysis detected a
better relapse-free survival (Log Rank 0.017) and breastival time (years) / n p-value, Log Rank
GASC1 positive
14.8/157 0.034 (0.005B, 0.010T-W)
14.9/65 0.168
14.5/92 0.098, (0.035 B, 0.052 T-W)
15.6/76 0.331
13.9/81 0.040 (0.013B, 0.018 T-W)
16.6/82 0.135
12.8/75 0.013 (0.002B, 0.004 T-W)
16.5/ 54 0.580
14.0/100 0.014 (0.003 B, 0.005 T-W)



















Figure 4 Time to relapse by Kaplan-Meier analysis. Overall, the patients with GASC1 immunopositive tumors have a longer time to relapse
than the patients with GASC1 negative tumors (p=0.034, Log Rank; p=0.005, Breslow; p=0.010 Tarone-Ware).
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with GASC1 positive tumors. In the Cox regression ana-
lysis after adjusting for age, stage, chemotherapy, hormonal
therapy and hormone receptor status, GASC1 positivity

















Figure 5 Time to relapse analysis by Cox regression. GASC1 negative c
The following covariates were included into the model: age at diagnosis, n
for the model is 0.000 and for the GASC1 status 0.002.relapse-free and better breast cancer specific survival
(Table 6). Overall survival was not affected by the GASC1
staining intensity.
Altogether sixty two patients with ER positive tumors





ases have a shorter time to relapse than GASC1 positive cases.
odal status, size of tumor, clinical stage and GASC1 status. The p-value
Table 4 GASC1 immunostaining according to histopathological and molecular parameters
Variable n GASC1 negative n (%) GASC1 positive n (%) p-value, chi2
Number of patients 355 198 (55.8) 157 (44.2)
Histological type
Ductal 231 143 (62) 88 (38) 0.005
Lobular 66 31 (47) 35 (53)
Rare 58 24 (41) 34 (59)
Histological grade
I 84 31 (37) 53 (63) 0.000
II 166 84 (51) 82 (49)
III 103 81 (79) 22 (21)
unknown 2
ER status
negative 77 51 (66) 26 (34) 0.033
positive 272 143 (53) 129 (47)
unknown 6
PR status
negative 137 91 (66) 46 (34) 0.001
positive 212 103 (49) 109 (51)
unknown 6
HER2 status
negative 290 156 (54) 134 (46) 0.029
positive 45 32 (71) 13 (29)
unknown 20
n – number of cases.
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postoperative radiotherapy. The mean duration of
tamoxifen therapy was 36 months (range 3–75). Forty
three patients received a daily dosage of 20 mg TAM
and 17 patients received a daily dosage of 40 mg TAM.
The Cox regression analysis revealed improved relapse-
free and breast cancer specific survival in those patients
with positive GASC1 staining (Table 6).
GASC1 staining status did not have any effect on the
survival of patients given chemotherapy as their only
medical adjuvant treatment (n=69). Furthermore, there
were no significant differences in overall survival in any
of the treatment groups (Table 6).GASC1 mRNA expression is in line with the
immunohistochemical data
The expression of GASC1 mRNA was evaluated in 57
available cases from the material used in tissue microar-
rays (TMA). The Kaplan-Meier survival curves were
similar to those obtained from protein analysis: cases
with low expression of GASC1 mRNA had 2.3 years
shorter breast cancer specific survival than cases with
high GASC1 mRNA expression (p=0.132, Log Rank;Figure 6). GASC1 mRNA expression in GASC1 nega-
tive cases was significantly lower than in GASC1 posi-
tive ones (Mann–Whitney: p=0.004). The expression
of GASC1 mRNA was significantly lower in grade II
and III tumors compared with its expression in grade I
tumors (Figure 7). This supports the previous find-
ing from TMA analysis showing that the great major-
ity (84%) of tumors of grade II and III were GASC1
negative.
The cases with negative or weak PR expression had a
significantly lower relative level of GASC1 mRNA than
the cases with high PR expression (Mann–Whitney:
p=0.016). In contrast, HER2 negative cases showed sig-
nificantly higher GASC1 mRNA expression than the
HER2 positive counterparts (Mann–Whitney: p=0.004),
which was in line with the protein staining results
(Figure 8).Discussion
This is the first study investigating GASC1 status in a
relatively large group of clinical samples (altogether 355
cases of invasive breast cancer). We show that GASC1
negativity is an independent prognostic factor of poorer
Table 5 Breast cancer specific survival by Kaplan Meier analysis according to histopathological and molecular
parameters
Variable n Means of survival time (years) / n p-value, Log Rank
GASC1 negative GASC1 positive
Overall 355 14.6/198 16.6/157 0.017 (0.012B, 0.013T-W)
Histological type
Ductal 231 14.5/143 17.3/88 0.006
Others 124 14.8/ 55 15.4/69 0.608
Tumor grade
I 84 16.5/ 31 17.0/ 53 0.415
II+III 269 14.3/165 16.0/104 0.087
unknown 2
ER status
negative 77 13.4/ 51 15.2/ 26 0.322
positive 272 15.0/143 16.7/129 0.043 (0.027 B)
unknown 6
PR status
negative 137 13.6/ 91 16.5/ 46 0.061 (0.042 B)
positive 212 15.4/103 16.5/109 0.251
unknown 6
HER2 status
negative 290 15.3/156 17.4/134 0.018 (0.003 B)
positive 45 12.1/ 32 13.0/ 13 0.704
unknown 20
HER2-/ductal/grade II 90 14.4/49 18.1/41 0.015
Triple negative 39 14.6/29 18.0/10 0.196
p- value for test of equality of survival distributions for the different levels of GASC1, B: Breslow (Generalized Wilcoxon),T-W: Tarone –Ware, n – number of cases.
Table 6 GASC1 and survival of breast cancer patients according to the type of adjuvant treatment
Cases n RFS BCSS OS
HR 95% CI p* HR 95% CI p* HR 95% CI p*
radiotherapy 206
negative 119 1§ 1§ 1§
positive 87 0.52 0.33 to 0.83 0.006 0.49 0.29 to 0.82 0.007 0.71 0.47 to 1.06 0.097
tamoxifen 62
negative 25 1† 1† 1†
positive 37 0.45 0.21 to 0.99 0.048 0.33 0.13 to 0.81 0.015 0.66 0.34 to 1.29 0.23
chemotherapy 69
negative 43 1‡ 1‡ 1‡
positive 26 0.64 0.29 to 1.38 0.25 0.70 0.30 to 1.64 0.41 0.81 0.36 to 1.82 0.60
RFS = relapse-free survival; BCSS = breast cancer specific survival; OS = overall survival.
*p was based on Cox proportional analysis.
§Reference value; HRs adjusted for age and stage at diagnosis, chemotherapy, hormonal treatment and hormone receptor status.
†Reference value; HRs adjusted for age and stage at diagnosis and radiotherapy.
‡Reference value; HRs adjusted for age and stage at diagnosis, radiotherapy and hormone receptor status.


















high GASC1 mRNA (n=20)
low GASC1 mRNA (n=37)
p=0.152
Figure 6 Breast cancer specific survival by Kaplan-Meier analysis. Overall, the patients with high expression of GASC1 mRNA in tumors have
a better survival than patients with low GASC1 mRNA expression (p = 0.152, Log Rank).
Histological grade






























Figure 7 Graph showing GASC1 mRNA expression in tumors of different histological grades. Boxes represent the 25–75th percentile;
whiskers: range; black line: median; black dots: outliers. The highest GASC1 mRNA expression is detected in tumors of grade I (GR I; 0.761±0.099).
Tumors of grade II (GR II; 0.510±0.070) and III (GR III; 0.510±0.069) show lower GASC1 mRNA expression than tumors of grade I. There is no
difference in GASC1 mRNA expression between tumors of grade II and III. Kruskal-Wallis test, p=0.02. Mann–Whitney test: grade I versus II -
p=0.006; grade I versus III - p=0.019, grade II versus III - p=0.821.
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A B
Figure 8 Graphs showing GASC1 mRNA expression according to progesterone receptor (PR) and HER2 status. (A) GASC1 mRNA relative
level is lower in tumors showing negative or weak expression of PR (0.483±0.051) compared with tumors showing high PR expression (0.691±
0.092; Mann–Whitney: p=0.016). (B) GASC1 mRNA relative level is higher in HER2 negative tumors (0.599±0.055) than in HER2 positive tumors
(0.326±0.054; Mann–Whitney: p=0.004).
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in groups of patients treated with different adjuvant
therapies, evidence of its prognostic as well as predictive
value for women with invasive breast cancer.
GASC1 negative women had poorer breast cancer spe-
cific survival, when they were in more advanced stages
of the disease (T2 – T4, positive lymph nodes, clinical
stages II - IV). However, the survival of women in initial
stages of the disease did not differ between GASC1 posi-
tive and negative cases, even though the percentage of
GASC1 positive tumors in these women was similar to
the percentage in women in more advanced stages of the
disease (results not shown). This observation points to a
modulating role for GASC1 in the regulation of gene
expression rather than a clear-cut activating or inhibi-
tory role. An interesting finding from the survival ana-
lysis was that HER2 negative patients survived
significantly better when they had GASC1 positive
tumors regardless of their clinical stage. This observa-
tion might point the search for new therapeutic possibil-
ities in the direction towards the GASC1 signaling
pathway. Identification of molecules involved in this
pathway and elucidating their role in the breast cancer
pathophysiology could well be beneficial especially for
those patients with triple negative tumors.
Moreover, we observed that GASC1 negative cases
overall and in advanced clinical stages had a shorter time
to relapse than the GASC1 positive patients, which was
in agreement with the breast cancer specific survival
analysis. Further, we demonstrated that the GASC1 posi-
tivity was statistically significantly associated with
improved relapse-free and breast cancer specific survival
in patients who were treated with adjuvant radiotherapyor with adjuvant tamoxifen which supported the above
results. Those patients with ER-positive, HER2-negative
disease are the group in whom decisions about adjuvant
chemotherapy are most difficult. The relative indications
for chemoendocrine therapy and endocrine therapy
alone are given by the St Gallen International Expert
Consensus [1]. However, there are no guidelines for
those ER-positive, HER2-negative patients who are node
positive with grade II tumors of size 2.1 – 5 cm (T2-T3).
Our results indicate that the patients with HER2 nega-
tive, grade II tumors of ductal type have better prognosis
when they are GASC1 positive (Table 5). Moreover
GASC1 positive patients respond better to hormonal
treatment. The results suggest that GASC1 positivity in
these patients might be an indication for endocrine ther-
apy alone, however this will need to be confirmed in a
larger group of patients.
The majority of GASC1 negative tumors were ductal
cases of higher histological grade, more often ER and PR
negative and HER2 positive. We confirmed these results
by analysis of GASC1 mRNA expression and we also
excluded the possibility that GASC1 is only a marker for
aggressive tumor subtype. As far as we are aware, there
are no studies of IHC GASC1 expression in human
breast cancer and therefore, we analyzed the list of genes
which were affected by GASC1 depletion in study of Loh
at al. [17] (Supplementary Table 1 by Loh at al. [17]).
Several genes which were up-regulated by GASC1 deple-
tion in this study have also been found to be up-
regulated in certain human tumors. Gene Sp5 (fold
change 4.8) was reported to be overexpressed in sev-
eral human tumors including hepatocellular carcinoma,
gastric cancer, and colon cancer [25,26]. Annexin A1
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oncogenic potential in breast cancer progression and
metastasis [27] and was significantly correlated with
unfavorable prognostic features of breast cancer [28].
Insulin-like growth factor-2 (IGF-2, fold change 4.5) and
H19 (fold change 4.2) are located together within an
imprinted domain of chromosome 11p15.5. Loss of
imprinting of IGF2 resulting in increased expression of
IGF-2 is a common genetic alteration in human malig-
nancies and aberrant methylation of IGF2/H19 locus has
been detected in multiple human cancers including
breast cancer [29-31]. Overexpression of IGF-2 was also
positively correlated with increased risk of breast cancer,
nodal positivity and higher tumor grade [32]. Forkhead
box Q1 (Foxq1, fold change 6.7) gene expression was
correlated with high-grade basal-like breast cancers
where it was associated with metastases and poor clinical
outcomes [33,34].
The above evidence suggests that the absence of
GASC1 might cause over-expression of several genes
responsible for carcinogenesis and a more aggressive
tumor phenotype in different cancers including breast
cancer, which supports our finding that GASC1 negativ-
ity is correlated with more aggressive breast tumors and
poorer prognosis. Based on these results, we speculate
that GASC1 and possibly its up- and/or downstream fac-
tors might help to define breast tumors with better or
poorer prognosis, especially in those which are consid-
ered to be more aggressive. However this hypothesis
needs confirmation in a larger group of patients.
GASC1 possesses enzymatic activity i.e. it specifically
demethylates tri- and dimethylated (me3 and me2) lysine
(K) in residues 9 and 36 on histone H3 (H3K9me3/2
and H3K36me3/2) [9,16,35] and together with histone
methyltransferases, it dynamically modulates the methy-
lation status of H3. The biological significance of H3
methylation depends on the modified residue (K9 or
K36), the degree of methylation (me1, me2, me3) and
the genomic position of H3 (promoter region or coding
region) [36,37]. In general, H3K9me3/2 is found in pro-
moter regions of inactive genes and demethylation in this
site triggers promoter activation, whereas H3K36me3/2
is enriched within the body of active genes and demethy-
lation in this site is related to the termination of tran-
scription [10,38]. However, the increase of H3K9me3
inactive mark in coding region of the gene has also been
associated with active gene expression [39].
The transcriptional repressive effect of the H3K9
methylation can be attributed to the association with the
repressive protein HP1 (heterochromatin protein 1) [11].
Cloos at al. [9] reported that GASC1 could effectively
demethylate H3K9me3 and H3K9me2, release the re-
pressive protein HP1 and reduce heterochromatin
in vivo. One could speculate that in the absence ofGASC1 HP1 would be recruited to H3K9me3/2 and
stabilize heterochromatin. Recent data have shown that
HP1α is over-expressed in numerous cancers and that
HP1α over-expression is associated with increased cell
proliferation, most likely through silencing of genes inhi-
biting cell proliferation. Moreover, the same authors
demonstrated that HP1α overexpression in breast cancer
patient samples correlated with an increased risk of death
[40]. These findings could explain, at least to some extent,
why GASC1 negativity is associated with more aggressive
tumors and poorer breast cancer specific survival.
H3K9me3 status is also mediated by different histone
methyltransferases. Suv39H1 (suppressor of variegation
3–9 homolog 1) is a major methyltransferase responsible
for H3K9me3 that is intimately linked to DNA methyla-
tion. Dong at al. (2012) have found that H3K9me3 and
DNA methylation on the E-cadherin promoter were
higher in basal-like breast cancer cell lines. Furthermore,
they showed that knockdown of Suv39H1 restored E-
cadherin expression by blocking H3K9me3 and DNA
methylation and resulted in an inhibition of cell migra-
tion, invasion and metastasis of basal-like breast cancer
[41]. GASC1 activity eliminates H3K9me3, which in
view of the above data, might partly explain the protect-
ive role of GASC1 evident in our data.
The role of GASC1 in prostate cancer has been stud-
ied by Wissmann at al. [16]. GASC1 colocalizes with
androgen receptor (AR) in both normal prostate and
prostate carcinomas. It enhances the transcription of AR
responsive genes, and this property may contribute to
tumor cell proliferation. In primary breast carcinomas,
including triple-negative breast cancer, AR expression
was interestingly associated with a significantly better
disease free interval and overall survival [42-44]. More-
over, AR positive breast tumors have been shown to be
smaller, more often node negative, lower in histological
grade and clinical stage than their AR negative counter-
parts [42-45]. The clinico-pathological characteristics of
AR positive tumors in the above studies resemble the
characteristics of the GASC1 positive tumors in our
study. This suggests that the GASC1 and the AR might
be functionally connected also in breast cancers. How-
ever, the effect of AR stimulation in breast tissue is
reported to be opposite to AR stimulation in prostate
[46].
Regardless of repressing or activating AR dependent
genes, GASC1 as an epigenetic factor can have a more
general influence on gene expression and it also may
modulate the expression of genes which are not
dependent on the AR.
GASC1 demethylase activity has been shown to regu-
late the expression of genes critical for stem cell self-re-
newal, including NOTCH1 and NANOG, and possibly
to be linked to the stem cell phenotypes in breast cancer
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tissue remodeling events occurring during puberty, preg-
nancy, lactation and menopause. Therefore, there needs
to be a compartment of normal stem cells or early pro-
genitor cells with high proliferative potential and differ-
entiation abilities in order to maintain the mammary
gland function. It has been proposed that breast tumors
arise from normal stem cells or early progenitor cells
through deregulation of normal self-renewal [47]. It is
possible that GASC1 maintains the normal population
of stem cells through mechanisms connected with HP1
regulation as described above. This function of GASC1
might be responsible for a lower recurrence rate in
GASC1 positive cases compared with the GASC1 nega-
tive and the better outcome of GASC1 positive patients
treated with radiotherapy.
The results obtained from clinical material are not con-
sistent with in vitro results from breast cancer cell lines. Liu
at al. [13] reported that GASC1 expression was significantly
higher in those cell lines representing aggressive basal-like
breast cancers compared with the cell lines representing
nonbasal-like breast cancers. Moreover, they demonstrated
that GASC1 was able to induce transformed phenotypes
when overexpressed in immortalized, non-transformed ER
negative mammary epithelial MCF10A cells. In our clinical
material, GASC1 positivity was associated with less aggres-
sive tumors. The reason for this discrepancy might be that
cell lines only generally reflect the pathophysiological envir-
onment of the tumor without including all the up- and
downstream factors present in the organism that influence
the tumor behavior. Liu and coworkers [13] linked the
above oncogenic properties of GASC1 with induction of
NOTCH1 by GASC1. However, there is evidence that
NOTCH proteins can act either as oncogenes or as tumor
suppressors depending on the cellular context [48,49]. One
reason for the difference between our results and the report
of Liu at al. [13] is that the latter did not take into account
the cellular context of GASC1 action i.e. stromal or physio-
logical interactions were absent in the cell cultures.
In addition to cell culture experiments, Liu at al. [13]
meta-analyzed data sets concerning gene expression in
human breast cancer from ONCOMINE. The results
concerning GASC1 mRNA expression from this meta-
analysis were consistent with their results obtained from
cell culture, but did not support our results from IHC
analysis of GASC1 expression. The discrepancy might be
attributed to differences in the studied material. The
data set from Fiank at al. [50] concerned gene expression
in tumor stroma, while we assessed GASC1 expression
in the epithelial compartment of the tumor. The analysis
which was based on material used by Kreike at al. [51]
consisted of 58% triple negative/basal like carcinomas,
while in our material, triple negative tumors constituted
only 11% of the total[51]. The discrepancy might alsocome from differences in methodology. We performed
immunohistochemistry and compared numbers of
GASC1 positive and negative tumors in different histo-
pathological and clinical groups, while Liu at al. based
their work on GASC1 mRNA and protein expression
analysis in different experimental setups. Our sample
size available for GASC1 mRNA expression study was
too small to permit a detailed statistical analysis, which
prohibits a relevant comparison between our GASC1 ex-
pression results with the GASC1 expression evaluated by
others.
Conclusions
In summary, this study shows that the histone demethylase,
GASC1, can have clinical significance as a prognostic as
well as a predictive factor, indicating better prognosis and
better response to radiotherapy and adjuvant treatment.
GASC1 can possess either tumor suppressing or oncogenic
properties, which may be context and organ specific.
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